Clinical trials
Myopathy clinical trials
Below are recruiting myopathy clinical trials, each written for real people, not researchers. We’re tracking 123 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07085104RecruitingPhase 1
Study of ALLO-329 for lupus, myositis, or scleroderma
This trial tests a new one-time cell therapy (ALLO-329) made from donor cells to target and calm overactive immune cells in people with lupus, myositis, or scleroderma that hasn't improved with usual medications. It aims to see if this treatment is safe and can help reduce disease activity.
Phoenix, ArizonaAges 18–74 - NCT07295847RecruitingPhase 1
Study of AZD0120 for autoimmune diseases
This trial tests if a new medication, AZD0120, is safe for people with autoimmune diseases. It aims to help patients by targeting the immune system.
Tucson, ArizonaAges 18–75 - NCT06371417RecruitingPhase 1
Testing RAY121 for several immune diseases (RAINBOW trial)
This trial tests a new medicine called RAY121 (an antibody) for people with certain autoimmune diseases. It aims to see if RAY121 is safe and how the body handles it. If you have one of these conditions and meet the basic health requirements, you might be able to join.
Orange, CaliforniaAges 18–85 - NCT06723106Enrolling by invitationPhase 1
Long-term safety study of RAY121 for immune conditions
This study is for people who already took RAY121 in a previous trial and did well. It tests whether continuing the treatment is safe and effective over a longer period. The goal is to manage chronic immune conditions.
Camperdown, New South WalesAges 18–85 - NCT04561557RecruitingEarly Phase 1
Cell therapy for relapsing nervous system autoimmune diseases
This early-phase trial tests CT103A “CAR-T” cell therapy to treat certain relapsing or treatment-resistant autoimmune diseases that affect the nervous system. It aims to see whether the cells are safe and may help reduce disease activity when standard treatments haven’t controlled symptoms.
Wuhan, HubeiAges 18–75 - NCT04703166Recruiting
iPredict study for atrial heart muscle changes over time
This study tracks how “atrial myopathy” (changes in the heart’s upper chambers) develops over time in people with atrial fibrillation or higher heart-risk. It uses special heart MRI pictures and regular follow-up to better predict progression, which may help future care planning.
New Orleans, LouisianaAges 18–79 - NCT04920812Recruiting
Testing multi-sample methods to diagnose mitochondrial muscle disease
This study looks for the cause of suspected mitochondrial diseases by combining multiple lab tests on muscle and skin samples, plus genetic testing results. If your current gene tests didn’t find an answer, this could help researchers learn what might be causing your condition.
Nice, CHU de NICEAges Any age - NCT05199740Recruiting
Testing treatment for people with certain mitochondrial DNA changes
This study looks at how much “mitochondrial DNA” mutation is in your body and what that means for people with specific genetic changes in muscle. It may help researchers better understand the condition and how to track response over time.
MaastrichtAges 18 years+ - NCT05211661Recruiting
Study breathing muscle changes in people on a ventilator
This study looks at how the diaphragm (a key breathing muscle) changes during and after being on a breathing machine in the ICU. It may help researchers understand why breathing can get weaker after ventilation and how to measure it safely (including with MRI).
AachenAges 18–75 - NCT05250375Recruiting
Study of mitochondrial muscle diseases over time
This natural history study follows children and adults with suspected or confirmed mitochondrial myopathy to better understand symptoms and how the condition changes. It may also include healthy participants to compare test results and improve future treatments.
Philadelphia, PennsylvaniaAges birth–100 years - NCT05454527Recruiting
Biobank study follow-up for adults with inflammatory muscle disease
This study follows adults who have (or are being evaluated for) inflammatory muscle conditions to collect health data and genetic test information. It may help researchers better understand these diseases and improve future care.
ParisAges 18 years+ - NCT05569122RecruitingPhase 1
Studying an MRI contrast method in mitochondrial muscle disease
This Phase 1 study tests a special MRI approach (using a contrast agent) to better measure changes in muscles in people with mitochondrial diseases. It also includes some healthy volunteers and other critically ill patients to compare results and check safety.
Philadelphia, PennsylvaniaAges 10–60 - NCT05895786RecruitingPhase 3
Study drug for active dermatomyositis or polymyositis
This Phase 3 trial tests how an investigational medicine (PF-06823859) works in adults with active dermatomyositis or polymyositis. It aims to improve disease control by targeting the immune system, but you must meet several safety and diagnosis requirements.
Glendale, ArizonaAges 18 years+ - NCT05982119Recruiting
Assessing muscle disease patients with activity monitors
This study assesses physical activity in people with different muscle diseases (like Duchenne, FSHD, and others) and in healthy volunteers. It helps doctors understand how these conditions affect daily movement and function.
LiègeAges 1–80 - NCT06092346Recruiting
Understanding rare purine and pyrimidine metabolism disorders
This study aims to learn more about rare disorders of purine and pyrimidine metabolism (DPPM), which can affect the brain, immune system, kidneys, and muscles. Researchers will study people with these disorders, their family members, and healthy volunteers to better understand the condition over time.
Bethesda, MarylandAges 1 month–100 years - NCT06249438RecruitingPhase 1
CAR-T cell therapy for hard-to-treat autoimmune diseases
This trial tests a new CAR-T cell therapy (C-CAR168) for people with several autoimmune diseases that have not responded to standard treatments. It aims to see if this therapy can control the disease when other medicines have failed.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06285539RecruitingPhase 2
Testing a drug for rare inflammatory diseases
This trial is testing a new drug (a JAK inhibitor) for people with rare inflammatory diseases like Behçet's, myositis, or IgG4-related disease that hasn't improved with standard treatments. The goal is to see if it can help control symptoms and reduce inflammation.
AmsterdamAges 18–65 - NCT06287762Recruiting
Natural history study of RYR1-related disorders
This study follows people with RYR1-related disorders over time to learn how the condition progresses. It may help researchers plan future treatments.
Bethesda, MarylandAges 7–100 - NCT06316076RecruitingPhase 1
CD19 CAR-T cell therapy for autoimmune diseases
This trial tests a new type of immune cell therapy (CAR-T cells targeting CD19) for people with autoimmune diseases that haven't improved with standard treatments. The goal is to see if it is safe and can help control the disease.
ShanghaiAges 18–65 - NCT06350110RecruitingPhase 1/Phase 2
CAR T cells for lupus
This trial tests a new type of CAR T cell therapy for people with active lupus that has not responded to other treatments. It uses specially engineered cells to target and eliminate certain immune cells that are causing the disease, with the goal of reducing symptoms and preventing flare-ups.
Beijing, Beijing MunicipalityAges 18–90 - NCT06379646Recruiting
YTS109 cell therapy for autoimmune disease
This study tests a new cell therapy (YTS109) for people with autoimmune diseases like lupus or Sjogren's syndrome that have not improved or keep coming back after standard treatments. It aims to see if the treatment can help control the disease.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT06455449RecruitingPhase 3
Injectable anifrolumab for polymyositis or dermatomyositis
This study tests a new injectable medicine (anifrolumab) added to your usual treatments for polymyositis or dermatomyositis. It may help reduce disease activity if you have moderate to severe symptoms and are already on stable therapy.
Phoenix, ArizonaAges 18–75 - NCT06479863RecruitingEarly Phase 1
Testing a new drug combo for inclusion body myositis
This trial tests a combination of two investigational drugs (pozelimab and cemdisiran) to see if they can help people with sporadic inclusion body myositis, a muscle disease that causes progressive weakness. If the drugs work, they may slow down the disease and help you stay stronger longer.
Austin, TexasAges 45–75 - NCT06502015Recruiting
Biomarkers in nervous system autoimmune diseases
This study looks for biomarkers (biological clues) in people with autoimmune diseases of the nervous system. It aims to discover better ways to diagnose and treat these conditions.
WuhanAges 18 years+
Hear when a new Myopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for myopathy?
- Yes. Clin2 currently lists 123 recruiting myopathy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a myopathy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a myopathy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.